The boards of directors for both companies unanimously approved the transaction.
Officials expect to close the deal by the end of February.
“[The transaction has allowed] us to not only accelerate our mission to discover, develop and deliver precision therapies to patients with rare cancers, but also deliver meaningful value to our shareholders through a substantial cash premium,” said President and CEO of ARIAD Pharmaceuticals Paris Panayiotopoulos. “This exciting transaction is a testament to the hard work and dedication of ARIAD’s talented team of employees. We have tremendous respect for Takeda, and I believe our shared commitment to innovation and research-driven cultures will provide for a smooth transition.”
More articles on supply chain:
Sen. Amy Klobuchar calls on Teleflex to fix defective naloxone spray
Novartis partners with Ionis Pharma for 2 heart drugs in $1B deal: 4 things to know
4 latest FDA approvals
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
